Epizyme inks screening deal with US Oncology Research
THE WOODLANDS, Texas & CAMBRIDGE, Mass.—August opened with the news that Epizyme Inc. and US Oncology Research had kicked off a collaboration for the screening and identification of relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) patients with EZH2 mutations. Per the agreement, US Oncology Research will use a screening protocol in 68 U.S. locations to identify qualifying patients and direct them to the trial for protocol screening. Eligible patients will be able to enroll in Epizyme’s ongoing Phase 2 clinical trial of tazemetostat, a first-in-class EZH2 inhibitor, as a single-agent treatment for relapsed/refractory FL or DLBCL.
Peter Ho, Epizyme’s chief medical officer, said that the collaboration “significantly expands our clinical trial footprint within the United States and is expected to further enhance our enrollment of patients whose tumors harbor an EZH2 mutation for our ongoing Phase 2 study of tazemetostat.”